The science behind Rogan's peptide choices Understanding why these particular peptides attracted Rogan's attention requires examining the underlying science
This precision-medicine approach helps determine whether you're a strong responder to GLP-1 therapy, whether you might benefit from dual-compound options, or whether additional pathways need addressing
Our team is here all day and night to answer questions and guide you home
A retrospective analysis of more than 110,000 women between the ages of 45 and 80 found that those who took GLP-1 medications were about 30 percent less likely to develop breast cancer than those who did not take GLP-1 medications, according to research presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 10506) by Elizabeth McDonald, MD, PhD, a professor of Radiology in the University of Pennsylvania Perelman School of Medicine and a practicing breast radiologist at Penns Abramson Cancer Center
Heart disorders and supplementation in cardiovascular disease Human skeletal and cardiac muscles contain relatively high concentrations of carnitine received from the plasma, since they are incapable of carnitine biosynthesis [1]
The effect typically begins within 4560 minutes after administration and may last for several hours